Screeninh hpv sarcina protocol

Women having primary HPV screening must be sent the screening leaflet ‘NHS Screening: Helping you decide’ and a copy of the leaflet for primary HPV screening together with their invitation letter. Screening Program recommend HPV testing for primary cervical screening, with cytology triage of HPV-positive results,8 though this practice has not yet been funded.9 A pilot study comparing HPV primary screening with Pap cytology screening, the HPV FOCAL trial, is ongoing in British Columbia; the results are expected to influence future policy decisions on cervical Gel Papillor. Implementation guide: primary HPV screening. Appendix 1: cervical screening protocol. hrHPV Test Re-screen in 12 months hrHPV positive cytology negative, inadequate or abnormal Colposcopy referral Re-screen in 12 months Colposcopy referral Colposcopy referral Routine recall. Routine recall. Routine recall. hrHPV negative hrHPV positive.

This builds on and replaces the short term mitigation guidance for providers implementing primary HPV screening to support cytology backlogs and the day turnaround time standard, which means.

Screeninh hpv sarcina protocol

Screeninh hpv sarcina protocol
Local training will be required to cover changes to processes required for sacina HPV screening, including but not limited to the ordering and supply of sample taking materials, sample transport, sample processing in laboratories and use of IT platforms. Explore the topic National Health Service Public health. What were you doing?

These are: consumables delivered by the manufacturer direct to local trust pathology departments where staff manage distribution to GP practices consumables delivered by the manufacturer direct to the centralised screening laboratory for onward distribution to GP protofol, usually once per year or once per quarter, including arrangements for ad hoc delivery if required centralised supplies solution with no laboratory involvement 6. Centralisation of screening laboratory services will lead to laboratories serving a larger number of GP practices, colposcopy clinics, sexual health services and histology laboratories, with many residing in different trusts. Criteria will be established for the use of the unavailable hrHPV test reporting code to make sure there is consistent reporting across laboratories. High-grade dyskaryosis moderateHPV positive, refer colposcopy.

Women Screeninh hpv sarcina protocol hrHPV positive at the first follow up test will have cytology performed and all will be referred to colposcopy if follow up is in primary care. Women with inadequate colposcopy examination are managed on the Screeninh hpv sarcina protocol of their referral screening test. Brexit Check Screeninh hpv sarcina protocol Go Check what you need to do. Pap-only testing every three years is acceptable, because the role Screeninh hpv sarcina protocol HPV testing is unclear after hysterectomy. Primary screening tests taken under private arrangements are managed in the following ways: Commissioners and providers may Screenunh to explore opportunities to speed up transportation and improve the tracking of samples. The NHSCSP has produced templates for the screening invitation and result letters associated with each type of result.

HPV Primary Screening Pilot Protocol Algorithm All women aged on routine call/recall and early recall HR-HPV Test HR-HPV -ve HR-HPV +ve Routine recall 3y() 5y(≥50) Cytology triage File Size: 91KB. screening program, based on HPV testing as a primary screening test. The purpose is to provide managers with up-to-date information on HPV testing, and to facilitate strengthening cervical Gel Papillor screening programs. It provides information on the natural history of HPV, characteristics of HPV tests, and a summary of WHO recommendations on screening and treatment of preGel Papillorous cervical. HPV primary screening means that a cervical screen sample is first tested for the presence of an HPV infection because almost all cervical Gel Papillor is caused by genital infection with HPV. HPV infection is very common and about four out of five people have an HPV infection at some time in their lives. NHS Cervical Screening Programme.

Cervical screening and Human Papillomavirus (HPV) testing. Public Health England leads the NHS Screening Programmes. This leaflet tells you about HPV testing. This is a test carried out on the sample of cells we take. during cervical screening. It makes no difference to what happens at your screening hpv.iubescstudentia.ro Size: KB.

HPV Screening and Follow-Up Protocol – Consult QD

New HPV implementation guidance for cervical screening providers - PHE Screening
Accept additional cookies Reject additional cookies View cookies. What went wrong? This protocol outlines the recommended process of primary screening for human papillomavirus HPV. Public Health England. If subsequently no result is obtained due to insufficient sample, this should be reported as HPV -U as above. Laboratories and screening and immunisation teams need to notify PCSE of: No cytology result, HPV not available, refer colposcopy. Look Screeninh hpv sarcina protocol for our upcoming blog which will provide further information.

Screeninh hpv sarcina protocol neoplasia non-cervicalHPV positive, refer colposcopy. CSPLs new to the role and those requiring further development should attend programme approved training.

All three cervical Gel Papillor screening methods provide highly effective Gel Papillor prevention, so it is important for providers to choose the strategy that best fits their practice. The most critical aspect of screening is getting all women screened, no matter which method is used. It is critical to remember that the screening intervals are intended for patients without symptoms. Those who have new concerns such as bleeding should have a diagnostic Pap done to evaluate their symptoms. Regardless of the pathway chosen, appropriate follow-up of any abnormal test result is critical to the early detection of Gel Papillor.

Established follow-up guidelines exist, 22,23 but accessing this information can be difficult for the busy clinician.
The app also includes the best screening algorithms for a particular patient. All guidelines agree that cervical Gel Papillor screening should start at age 21, regardless of HPV vaccination status or age of sexual initiation. For women who have had a total hysterectomy and no history of cervical neoplasia, screening should be stopped immediately after the procedure.
However, several high-risk groups of women will need continued screening past the age of 65, or after a hysterectomy. For a woman with a history of stage two cervical intraepithelial neoplasia or higher grade lesions, routine screening is continued for an additional 20 years, even if she is over age Pap-only testing every three years is acceptable, because the role of HPV testing is unclear after hysterectomy.

Many gynecologic oncologists will recommend that women with a history of cervical Gel Papillor continue annual screening indefinitely.
Within the first two to three years after treatment for high-grade dysplastic changes, annual follow-up is done by the gynecologic oncology team. Providers who offer follow-up during this time frame should keep in communication with the oncology team to ensure appropriate, individualized care. There is no override facility for individual cases beyond those described below and so it is not possible to recall women at shorter or longer intervals than those defined in the protocol.
Where there is uncertainty over the quality of the sample, these should be rejected, or accepted and reported in accordance with guidance detailed in section Samples accepted but requiring a repeat sample in 3 months must be coded as XUR or 19R as appropriate.

Code combination X0R must not be used for tests requiring 3-month repeat as it will be implemented as the default recall interval of 36 months. There are 2 valid recall intervals applicable to tests coded X0R, 29R and 09R. In each case, the woman could require recall in either 12 or 36 months.
A default interval will apply to these results although an allowable alternative can be provided by the laboratory which will override the default value. The defaults and allowable override values are: Test results will be rejected by the call or recall system if they are flagged as primary hrHPV tests and: It is recommended that the laboratory LIMS incorporates basic validation to prevent the issue of these results where possible. Women will be called for screening from age Women are currently screened every 3 years between the ages of The UKNSC is considering the evidence to support extending screening intervals for all women in the screening age range.

Women recalled for a repeat screen at 12 months due to being hrHPV positive with negative cytology at their preceding test will have a repeat hrHPV test.
All hrHPV positive women will have cytology triage performed on their sample. Those with abnormal cytology will be referred to colposcopy. Women with negative cytology will be recalled for a further 12 month repeat test 24 months from the initial screen. Women returning for a second repeat test, 24 months since the initial screening test, will receive an hrHPV test. Cytology performed here defines the urgency of referral required and assists the colposcopist.
A gynaecological referral must be made for women with a cytology result of?

These women will be followed up for their hrHPV positive result in the same way as women with negative cytology by repeat screening at 12 and 24 months. When the hrHPV test result is unavailable or cytology is inadequate at any screening episode in the pathway, the sample will be repeated in no less than 3 months. Women who have an inadequate cytology test at the 24 month repeat test are an exception and will be referred to colposcopy. Women with 2 consecutive hrHPV unavailable or cytology inadequate screening tests in any combination will be referred to colposcopy. Cytology will not be performed on any sample where an hrHPV positive result has not been obtained exception in the case of novice sample takers see section This includes samples from women attending for 12 month repeat tests.
Guidance on the criteria for assessing cytological adequacy will be published shortly on GOV.

Women recently treated for cervical intraepithelial neoplasia CIN or cervical glandular intraepithelial neoplasia CGIN prior to the implementation of HPV primary screening should be managed according to the colposcopy management recommendations for the implementation of primary hrHPV screening see section 14 and appendix 2. Follow up differs slightly to the test of cure protocols used previously, most notably in that cytology is not required for hrHPV negative women. Women being followed up for untreated CIN1 should also be managed by hrHPV testing according to the colposcopy management recommendations for the implementation of hrHPV primary screening see section Women who have completed follow up protocols when primary hrHPV testing is implemented and are returning for their next test 36 months later will begin a new screening episode, according to the primary hrHPV screening protocol algorithm.

Women part way through follow up for cervical Gel Papillor who still have a cervix should be managed by hrHPV testing at their next test and not continue with cytology-based follow up. HIV positive women within the screening age range are eligible to be screened annually and should be invited for screening using hrHPV as the primary test rather than cytology. The management of these women will follow the protocols for primary hrHPV testing in all other aspects other than frequency of screening. At the current time, these women remain in the programme according to screening protocols. Laboratories providing primary hrHPV testing and cytology triage to the NHS screening programme will be required to use a system of direct referral of women to colposcopy.
Direct referral reduces anxiety for women by speeding up the patient journey and facilitates improved management of clinics, reducing waiting lists and non-attender rates.

An efficient system needs to be in place to correctly identify the appropriate colposcopy clinic to send the referral and ensure it is received. Women with an intact cervix who have received radiotherapy of the pelvic region for example for anal, cervical, low colorectal and vaginal Gel Papillors which means that an adequate sample cannot be obtained, are not eligible for cervical screening using primary hrHPV testing. They can be ceased from the programme.
For further information see guidance for ceasing women from the programme. Where a woman has defaulted colposcopy following high grade abnormalities and attends for screening 12 months later through the failsafe process, she should be re-referred to colposcopy even if her result is hrHPV negative. If, however, she has defaulted colposcopy following low grade abnormalities she does not warrant re-referral to colposcopy if her result if hrHPV negative; her management will follow the usual national protocol.

Women who have a private screening test remain eligible for NHS testing at appropriate intervals subject to a minimum of 3 months between samples. Primary screening tests taken under private arrangements are managed in the following ways: Women who are due or overdue for their NHS test should be encouraged to take up their screening following a private HPV positive result. The recommended management pathways and follow up for women being referred to colposcopy following abnormal results from primary HPV screening are summarised in Appendix 2. The implementation of primary HPV screening pathways leads to an increased number of colposcopy referrals.
This compared to 3. The impact of recalling women at 12 and 24 months following HPV positive results with negative cytology amounted to an extra 1. The first full school-based cohort of vaccinated women entering the programme in will impact this.

Women with inadequate colposcopy examination are managed on the results of their referral screening test. Those with borderline changes in endocervical cells and high-grade dyskaryosis or worse cytology will be offered a large loop excision of the transformation zone LLETZ procedure. Women with no biopsy taken, a biopsy showing no CIN , or where there was no colposcopic impression of CIN will be recalled in 36 months if their referral cytology results were negative, borderline changes in squamous cells or low-grade dyskaryosis.
Women referred with borderline changes in endocervical cells and high-grade dyskaryosis or worse should have their case discussed and management agreed at the colposcopy multidisciplinary team meeting within 2 months.

If CIN is confirmed on biopsy or there is colposcopic impression of CIN1 without a biopsy, the woman will be managed according to the same protocols as women with an abnormal colposcopic appearance, detailed in the following sections. The management recommendation for women who have a colposcopic appearance consistent with CIN1 or CIN1 confirmed on biopsy is recall for screening in primary care in 12 months with hrHPV testing.
Women testing hrHPV negative at this repeat test can be recalled in 36 months, at which point they will re-start the screening protocol for primary HPV testing. Women testing positive for hrHPV at the 12 month repeat test will have cytology performed on their sample and if this is abnormal any grade they will be referred to colposcopy again. At the second repeat test women who are hrHPV negative can be recalled in 36 months. Those who are hrHPV positive will have cytology performed.

Those testing negative for cytology can also be recalled in 36 months when they will restart the screening protocol for primary HPV testing. Women with abnormal cytology will be referred to colposcopy. Those testing hrHPV negative will be recalled for screening in 36 months when they will restart the screening protocol for primary hrHPV testing. Women who test hrHPV positive will have cytology performed but will all be referred to colposcopy again regardless of the cytology result. Rarely, women may be offered conservative management for CIN2. Such women must remain subject to close colposcopic follow up in a clinic. If screening samples are taken during this time, they will be primary hrHPV tested by the laboratory with cytology performed if hrHPV positive.
All samples will initially be tested for hrHPV and those women testing negative will be recalled for the second follow up test in a further 12 months.

Cytology is not required in hrHPV negative women to confirm the presence of endocervical cells. Women testing hrHPV positive at the first follow up test will have cytology performed and all will be referred to colposcopy if follow up is in primary care. The cytology samples from these hrHPV positive women must contain endocervical cells to be considered adequate for cytology unless they contain abnormal cells. Women who have negative cytology and normal colposcopic appearance will be recalled for the second follow up test in a further 12 months.
At the second follow up test women testing hrHPV negative will be recalled for further testing in 36 months, when they will restart the screening protocol for primary hrHPV testing. Women testing hrHPV positive at the second follow up test will have cytology performed and all will be referred to colposcopy if follow up is performed in primary care.

Women with abnormal cytology at either of the 2 follow up tests will be re-referred to colposcopy. In those women where colposcopy is found to be normal or re-excision does not occur, 10 years follow up should be completed with annual hrHPV testing.
All women re-referred to colposcopy due to a hrHPV positive result will be eligible to enter the CGIN post treatment follow up pathway again if they have further re-excision with complete excision margins. Follow up in clinic is recommended, however, should follow up occur in primary care an hrHPV positive result must result in a re-referral to colposcopy regardless of the cytology result. Follow up samples should be taken at least 6 months following treatment and attending early should be discouraged. Samples taken less than 3 months post treatment must not be tested.

Women being followed up for cervical Gel Papillor and who still have a cervix will be followed up with hrHPV testing at 6 and 12 months and then annual follow up for a further 9 years. These women are usually on clinical follow up, however, should follow up testing occur in primary care an hrHPV positive result must result in a re-referral to colposcopy regardless of the cytology result.
Follow up after radical trachelectomy for cervical Gel Papillor is outwith the remit of the cervical screening programme. The arrangements for follow up of these women remain within the remit of the commissioning of and provision of local gynaecological Gel Papillor services. If the gynaecological oncology services wish to offer cytological follow up for women after radical trachelectomy then this is a local decision.

If cytology is required as the primary test and not HPV , the gynaecological Gel Papillor service should negotiate with the relevant cytology laboratory and the Gel Papillor service commissioners to find a mechanism to provide this service. The centralisation of screening laboratory services will require the consideration of a number of issues required for the continuation of the screening service across previous boundaries.
Where laboratories are to merge, or individual systems are to be decommissioned, providers must provide plans for the safe transition of data into a single system or have alternative plans to ensure continued, appropriate access to data from legacy or decommissioned systems for failsafe, audit and data reporting purposes. The providers involved must also agree who will complete the KC61 and other outstanding data returns for the population of women transferred to the new service.

This may depend upon the time of year when the service transfers and SQAS will be able to advise on the most pragmatic approach. Arrangements must be in place to ensure that the data needed for the retrospective elements of the KC61 can be obtained.
Cervical cytology slides are retained and stored for a period of 10 years following reporting for review purposes. As screening services relocate to larger centralised laboratories, provision must be made to maintain these slide archives, which remain the responsibility of the trust that reported them. Whether the archive is moved to the new screening laboratory or maintained in the current site an SLA must be put in place to ensure continued prompt access when required. Any issues arising from these slides in the future, for example, findings from invasive Gel Papillor audits, remain the legal responsibility of the provider that reported them.

The responsibility for carrying out audits of invasive cervical Gel Papillor will remain with the provider, and thus the CSPL, where the woman was diagnosed. The centralised screening laboratory must agree to arrangements or procedures for providing slide review opinions to the provider hosting the services where women are diagnosed. This may include accessing and reviewing archived slide material originally reported at another provider as detailed above in Where archived material has been produced using a different LBC technology to that used in the screening laboratory, arrangements must be put in place for these reviews to be performed by an individual qualified to report the LBC type.
The provider must agree who will take responsibility and provide clear arrangements for the provision of laboratory failsafe for women referred to colposcopy during the 12 months prior to the transfer of screening laboratory services.

Consideration must be given to the management of samples received shortly before the implementation of primary HPV screening and cytology backlogs present within screening laboratories. These samples must be primary cytology screened and provision must be made to ensure these samples are screened, hrHPV tested where applicable and reported promptly. Services transferring elsewhere may require the continuation of the laboratory service for a period of time purely for the purpose of screening all recent samples and clearing backlogs.
The role of CSPLs will require review to become aligned with the services delivered by the provider following the reorganisation of screening laboratory services. Role descriptions and meeting terms of reference and arrangements may need to be revised to take account of the changes.

Where the laboratory has traditionally hosted the sample taker register, agreements must be put in place, in collaboration with the relevant SIT , to ensure the provision of this once the laboratory service has transferred to a centralised laboratory. Systems of direct referral must be established for women referred from the screening laboratory service to colposcopy services both within and across provider boundaries as defined by zonal commissioning arrangements.
The causal relation between human papillomavirus and cervical Gel Papillor. Journal of Clinical Pathology, , International Journal of Gel Papillor ; 1. Human papillomavirus and Papanicolaou tests to screen for cervical Gel Papillor. New England Journal of Medicine ; Efficacy of human papillomavirus testing for the detection of invasive cervical Gel Papillors and cervical intraepithelial neoplasia – a randomised controlled trial.

Lancet Oncology ; 11 3. Lancet Oncology ;10 7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England – extended follow-up of the ARTISTIC randomised trial cohort through 3 screening rounds. Health Technology Assessment ; 18 Page 1 to To help us improve GOV. It will take only 2 minutes to fill in.
Cookies on GOV. UK We use some essential cookies to make this website work. Accept additional cookies Reject additional cookies View cookies. Hide this message.

Skip to main content. Public Health England. Contents 1. Introduction 2. Roles and responsibilities 3. Service reconfiguration 4. Preparation for implementing primary HPV screening 5. Information materials 6.
Cervical screening samples 7. Screening laboratories 8. Screening tests 9. Quality assurance of HPV testing Training IT system changes Protocols for screening women with primary hrHPV testing Protocols for managing women referred to colposcopy Centralisation of screening laboratories References Print this page. Roles and responsibilities 2. The main elements of this work include: developing quality standards and guidance for the cervical screening programme developing the Section 7a service specification no.
Service reconfiguration The implementation of primary HPV screening into the cervical screening programme will lead to a reduction in the amount of cervical cytology performed.

Preparation for implementing primary HPV screening All elements of local cervical screening programmes will need to be engaged well in advance of implementation. Consideration should be given to the following areas prior to implementation.
Start dates must be agreed with all elements and disciplines of the local programmes and any programmes where work is being transferred or centralised prior to implementation. This includes all laboratory screening services that will be transferred or centralised and their associated primary care services via CCGs. The sequencing of events with respect to work transferring from one screening laboratory to another needs careful planning. Laboratories will need to generate excess cytology capacity by converting their own screening work to primary HPV screening prior to receiving work transferred in from laboratories ceasing to provide cervical screening.

Where implementation is staged, GP practices and colposcopy services that are not yet involved in primary HPV screening but straddle other programme areas that are, need to be alerted to the possibility of being contacted by patients about primary HPV screening.
PCSE must be engaged at an early stage around 12 weeks ahead to ensure that they are ready to identify cohorts of women and issue appropriate invitations 6 weeks in advance of the start date , information and result letters to support the new reporting codes. Adequate sample logistics are required where work has been transferred or centralised to ensure the continued supply of sample test kits to primary care services and the timely collection and relay of samples to the laboratory see section 6. The screening laboratory should ensure that systems and contracts are in place in time for the start date for a new population of women.

An understanding of the primary HPV protocol and procedures required is essential and training must be provided and completed by all staff, including primary care and other sample takers, laboratory and colposcopy staff see section Cervical screening programme approved platforms for hrHPV and liquid based cytology must be selected, and arrangements made with suppliers to ensure supply of sufficient consumables, capacity planning, and the installation, checking, verification, validation and training on any new equipment is completed in advance see section 8. Programmes should be alert from the outset to the full implications of primary hrHPV testing for local IT processes. Additions to laboratory information management systems LIMS , middleware and messaging will be required to support the new reporting code set see section Results sent by other methods for example email or paper will not be accepted by PCSE.

Arrangements must be made prior to the transfer of laboratory services to address issues relating to backlogs, access to archival slide material and screening records see section Ensuring capacity in all organisations providing colposcopy, to accommodate additional colposcopy appointments required to support the primary HPV screening pathway see section 13 and section Local protocols in primary care, laboratories and colposcopy services must be rewritten to reflect all the changes required for primary HPV screening. New programme standards and guidance will to be implemented alongside primary HPV screening and appropriate data flows created to ensure compliance can be demonstrated.
Information materials 5. Cervical screening samples 6. All staff involved in the process of sample transportation must receive training.

Existing methods of sample transportation Existing services involve: local hospital trust operated laboratory transport systems collecting samples from GPs at least once a day and delivering to the sample reception at the local trust pathology department sorting of cervical screening samples at the local trust provision of transportation by the trust hosting the centralised laboratory to collect samples from local trusts and transport to the centralised laboratory service sample reception, at least once per day The application of lean principles to transport processes is common, for example in the use of colour coded transport boxes and specimen bags.
Opportunities to improve the transportation of samples Commissioners and providers may want to explore opportunities to speed up transportation and improve the tracking of samples.

These include: electronic barcode tracking of sample bags can be facilitated with some LIMS systems, providing additional security and an audit trail of the transportation process universal implementation of GP electronic test requesting, including a process to provide the past screening history as detailed on Open Exeter at sample taking source, to support sample log in process Royal Mail or external courier delivery of samples from local trusts to centralised screening laboratories in terms of speed, costs, environmental impact and regulation compliant packaging 6.
The model of distribution implemented must: be reliable and efficient provide a means for sample takers to order consumables record batch numbers on consumables to enable identification, should any issues or incidents arise Existing methods of consumables distribution Models of distribution exist within the cervical screening programme. These are: consumables delivered by the manufacturer direct to local trust pathology departments where staff manage distribution to GP practices consumables delivered by the manufacturer direct to the centralised screening laboratory for onward distribution to GP practices, usually once per year or once per quarter, including arrangements for ad hoc delivery if required centralised supplies solution with no laboratory involvement 6.
Screening laboratories 7. Screening tests 8. Under no circumstances should a test be repeated in less than 3 months.

SQAS must be provided with evidence that: training is provided on site all staff undertaking testing complete training staff have a certificate of completed training If a laboratory decides to adopt more than one hrHPV testing method, staff must be trained to required level of competence in each of the tests used. Course topics include: results of randomised controlled trials and pilots of primary hrHPV testing primary hrHPV screening protocols and management algorithms hrHPV test and cytology workflow through the laboratory quality assurance These elements will need to feature in programme update training.


UK, remember your settings and improve government services.

We sarcinz use cookies set by other sites to help us deliver content from their services. You can change your cookie settings at any time. This publication is licensed under the terms of the Open Government Licence v3. To view Screeninh hpv sarcina protocol licence, visit nationalarchives. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Infection with a high-risk strain of the human papillomavirus has been established as a necessary but insufficient cause of cervical Gel Papillor [footnote 1]. This has led in recent years to the inclusion of hrHPV testing as an adjunct to cytology in organised cervical screening programmes. In the English programme hrHPV testing has been used since to help manage women with low grade cytology abnormalities and as a follow up test of cure in women who have received treatment.

Four large European randomised controlled trials have considered the use of hrHPV testing as a primary screening test. As natural history work suggests that at least 10 years elapses between acquiring hrHPV and developing sarciina, the high negative predictive value of hrHPV testing and lower false negative rate means screening intervals can be lengthened in women who test Screeninh hpv sarcina protocol for hrHPV. This evidence provides the rationale for moving to primary testing with hrHPVreserving cytology for women Screeninh hpv sarcina protocol hrHPV Screeninh hpv sarcina protocol. The implementation of primary Sarcinq screening is a major undertaking that will impact upon all elements of the programme and require significant service redesign.

New HPV implementation guidance for cervical screening providers

Human papillomavirus (HPV): primary screening protocol

Cleveland Clinic is a non-profit academic protocoll center. Advertising on our site helps support our mission. We do Screeninh hpv sarcina protocol endorse non-Cleveland Clinic products Screeninh hpv sarcina protocol services Policy. The USPSTF reviewed large randomized and observational studies to summarize the effectiveness of the three screening strategies and commissioned a decision analysis model protoccol compare the risks, benefits and costs of the three screening algorithms. The guideline statement notes both cotesting and high-risk HPV testing offer similar Gel Papillor detection rates: each prevents one additional Gel Papillor per 1, women screened as opposed to Pap-only testing.

Also, tests that incorporate high-risk HPV screening may offer better detection of cervical adenocarcinoma which has a worse prognosis than the more common squamous cell carcinoma type. However, both HPV-based screening strategies are more likely to require additional colposcopies for follow-up than Pap-only screening 1, colposcopies protocl for each Gel Papillor prevented with high-risk HPV alone, 1, with cotesting.

Faci un comentariu sau dai un răspuns?